Fig. 2From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemiaECL bioanalytical method for the detection of ADAs during ALL studies. ADA = anti-drug antibody; ALL = acute lymphoblastic leukemia; ECL = electrochemiluminescence; MSD = Meso Scale DiscoveryBack to article page